Health Care [ 8/12 ] | Pharmaceuticals [ 50/74 ]
NASDAQ | Common Stock
Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally.
The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline), a tetracycline class antibacterial for the treatment of complicated intra-abdominal infections in adults; XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia; and ZEVTERA, a cephalosporin antibacterial for the treatment of adult patients with staphylococcus aureus bloodstream infections, adult patients with acute bacterial skin and skin structure infections, and adult and pediatric patients with community-acquired bacterial pneumonia.
Its development pipeline includes Zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea.
Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP.
It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma.
The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016.
Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 26, 25 | 0.26 Decreased by -65.79% | 0.41 Decreased by -36.59% |
| Nov 4, 24 | 0.02 Decreased by -97.96% | 0.26 Decreased by -92.31% |
| Jul 31, 24 | -0.55 Decreased by -2.85 K% | 0.24 Decreased by -329.17% |
| May 8, 24 | 0.46 Increased by +9.52% | 0.17 Increased by +170.59% |
| Feb 29, 24 | 0.76 Increased by +177.55% | 0.23 Increased by +230.43% |
| Nov 1, 23 | 0.98 Decreased by -65.00% | 0.27 Increased by +262.96% |
| Aug 2, 23 | 0.02 Decreased by -60.00% | 0.26 Decreased by -92.31% |
| May 9, 23 | 0.42 Increased by +20.00% | 0.23 Increased by +82.61% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 91.81 M Increased by +2.84% | 20.33 M Decreased by -66.96% | Increased by +22.15% Decreased by -67.87% |
| Sep 30, 24 | 89.51 M Increased by +33.08% | 1.21 M Decreased by -98.52% | Increased by +1.36% Decreased by -98.89% |
| Jun 30, 24 | 103.35 M Increased by +27.61% | -34.69 M Decreased by -2.81 K% | Decreased by -33.56% Decreased by -2.22 K% |
| Mar 31, 24 | 80.95 M Increased by +6.00% | 36.53 M Increased by +4.78% | Increased by +45.13% Decreased by -1.15% |
| Dec 31, 23 | 89.27 M Increased by +35.67% | 61.53 M Increased by +190.07% | Increased by +68.93% Increased by +166.39% |
| Sep 30, 23 | 67.26 M Increased by +0.00% | 82.05 M Decreased by -69.10% | Increased by +121.99% Decreased by -69.10% |
| Jun 30, 23 | 80.99 M Decreased by -25.16% | 1.28 M Increased by +36.32% | Increased by +1.58% Increased by +82.14% |
| Mar 31, 23 | 76.37 M Decreased by -15.20% | 34.87 M Increased by +121.04% | Increased by +45.65% Increased by +160.66% |